Toralizumab structure
|
Common Name | Toralizumab | ||
|---|---|---|---|---|
| CAS Number | 252662-47-8 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ToralizumabToralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive drug, has the potential for active systemic lupus erythematosus (SLE) research[1][2]. |
| Name | ANTI-CD154 |
|---|
| Description | Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive drug, has the potential for active systemic lupus erythematosus (SLE) research[1][2]. |
|---|---|
| Related Catalog | |
| Target |
CD40L |
| References |
| Appearance of Characters | lyophilized powder |
|---|---|
| Storage condition | −20°C |